The Ameliorative Effect of COST on Diet-Induced Lipid Metabolism Disorders by Regulating Intestinal Microbiota

Mar Drugs. 2022 Jul 7;20(7):444. doi: 10.3390/md20070444.

Abstract

Background: Chitosan oligosaccharides, with an average molecular weight ≤ 1000 Da (COST), is a natural marine product that has the potential to improve intestinal microflora and resist lipid metabolism disorders.

Methods: First, by establishing a mice model of lipid metabolism disorder induced by a high fat and high sugar diet, it is proven that COST can reduce lipid metabolism disorder, which may play a role in regulating intestinal microorganisms. Then, the key role of COST in the treatment of intestinal microorganisms is further confirmed through the method of COST-treated feces and fecal bacteria transplantation.

Conclusions: intestinal microbiota plays a key role in COST inhibition of lipid metabolism disorder induced by a high fat and high sugar diet. In particular, COST may play a central regulatory role in microbiota, including Bacteroides, Akkermansia, and Desulfovibrio. Taken together, our work suggests that COST may improve the composition of gut microbes, increase the abundance of beneficial bacteria, improve lipid metabolism disorders, and inhibit the development of metabolic disorders.

Keywords: chitosan oligosaccharides; diet; disorders lipid metabolism; gut microbes.

MeSH terms

  • Animals
  • Bacteria
  • Diet, High-Fat / adverse effects
  • Gastrointestinal Microbiome*
  • Lipid Metabolism
  • Lipid Metabolism Disorders*
  • Mice
  • Mice, Inbred C57BL
  • Sugars

Substances

  • Sugars

Grants and funding

This work was financially supported by the Science and Technology Program of Guangzhou, China (NO.202103000089), the Guangdong Demonstration Base for Joint Cultivation of Postgraduates (2019), the Science Foundation for Distinguished Young Scholars of Guangdong (2020B1515020026), the National Natural Science Foundation of China (21804025).